Pfizer hit a new 52-week high of $29.09 on Tuesday, and the stock last traded at $28.75. That leaves the shares up roughly 20% year to date, marking a notable advance for a company that has spent much of the past two years working through the post-COVID revenue decline.

Pfizer Inc. (PFE) also recorded trading volume of more than 8.3 million shares on the day, above typical levels and a sign of renewed investor interest.

The move followed a strong Q2 2026 earnings report. Pfizer posted adjusted earnings per share of $0.77, beating Wall Street expectations of $0.68 by $0.09. Revenue reached $15.03 billion, ahead of the $14.42 billion consensus estimate. Revenue rose 2.6% from the same quarter a year earlier.

After the results, Pfizer raised its full-year 2026 EPS guidance to a range of $2.80 to $3.00. Analysts currently expect the company to report full-year earnings of $2.98 per share. Erste Group Bank also raised its fiscal 2026 EPS estimate for Pfizer after the report.

One of the major developments this week was the resolution of the Depo-Provera litigation. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging that the contraceptive was linked to intracranial meningioma. The company did not disclose the financial terms and did not admit liability. Still, the settlement removes a significant legal overhang that investors had been following closely, alongside the company’s broader effort to stabilize results as newer products and pipeline assets take on a larger role.

Pfizer’s oncology business remains another area of focus for analysts. Padcev is currently the growth leader in that segment, and the company also has pipeline programs including PF-08634404 that could support longer-term revenue. Label expansions in oncology are also being watched as a possible offset to pressure elsewhere in the business as older products face generic competition.

On the dividend side, Pfizer paid $0.43 per quarter on September 1 to shareholders of record as of July 24. That works out to an annualized dividend of $1.72 and a yield of about 6%.

The dividend has helped keep PFE on the radar of investors looking for income-generating names while tech and AI valuations remain elevated.

Analyst sentiment remains mixed. Royal Bank of Canada upgraded Pfizer from underperform to sector perform in June. HSBC downgraded the stock from buy to hold in July and lowered its price target from $32 to $28. Cantor Fitzgerald has a neutral rating with a $27 target, while Wolfe Research rates the stock underperform with a $26 target.

Overall, the consensus rating is “Hold,” with an average price target of $28.28, slightly below the stock’s current trading level.

Institutional investors own 68.36% of Pfizer. Several smaller funds added new positions in the first and second quarters of 2026.

The stock’s 50-day moving average is $25.62, while its 200-day moving average is $26.30, both below the current share price.